Top

Cancer Immunology, Immunotherapy

Published in:

01-01-2019 | Original Article

CD19⁺ tumor-infiltrating B-cells prime CD4⁺ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer

Authors: Qi Jiang, Qiang Fu, Yuan Chang, Zheng Liu, Junyu Zhang, Le Xu, Yu Zhu, Yiwei Wang, Weijuan Zhang, Jiejie Xu

Published in: Cancer Immunology, Immunotherapy | Issue 1/2019

Abstract

Purpose

CD19⁺ tumor-infiltrating B-cells (CD19⁺ TIB) play a crucial role in tumorigenesis, but their clinical relevance in muscle-invasive bladder cancer (MIBC) remains unknown. This study aimed to investigate the prognostic value of CD19⁺ TIB for post-surgery survival and adjuvant chemotherapy response in MIBC.

Experimental design

We assessed TIB by immunohistochemical staining of CD19 in 246 MIBC patients from Zhongshan Hospital and Shanghai Cancer Center. We evaluated the survival benefit of platinum-based chemotherapy according to CD19⁺ TIB. The mechanism underlying CD19⁺ TIB antitumor immunity was explored through the Cancer Genome Atlas (TCGA) dataset analysis and an in vitro Ag presentation assay.

Results

CD19⁺ TIB extensively infiltrated into the tumor stroma of MIBC. Adjuvant chemotherapy (ACT) led to a significantly increased benefit in the high CD19⁺ TIB MIBC patients (P = 0.003). In multivariate analysis, high CD19⁺ TIB MIBC patients had significantly longer OS with ACT in the discovery set (HR = 0.487, P = 0.038). TCGA gene expression analyses showed enrichment of adaptive immunity, T-cell-mediated immunity, and antigen-presentation signaling pathways in high CD19⁺ TIB MIBC patients. Moreover, CD19⁺ TIB co-localized with activated CD4⁺ TIT and expressed surface markers characteristic of antigen-presenting cells. Finally, an antigen-presentation assay demonstrated the antigen-presentation function of CD19⁺ TIB.

Conclusion

CD19⁺ TIB was identified as an independent prognostic factor, which could predict for post-surgery survival and platinum-based ACT benefits in MIBC. CD19⁺ TIB serve as antigen-presenting cells (APCs) to activate CD4⁺ TIT in the tumor environment of MIBC.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387 CrossRefPubMed

Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A, Group EGW (2014) Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25 Suppl 3: iii40–i8. https://doi.org/10.1093/annonc/mdu223 CrossRefPubMed

Witjes JA, Comperat E, Cowan NC et al (2014) EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 65:778–792. https://doi.org/10.1016/j.eururo.2013.11.046 CrossRefPubMed

Alfred Witjes J, Lebret T, Comperat EM et al (2017) Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 71:462–475. https://doi.org/10.1016/j.eururo.2016.06.020 CrossRefPubMed

Pylayeva-Gupta Y, Das S, Handler JS, Hajdu CH, Coffre M, Koralov SB, Bar-Sagi D (2016) IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov 6:247–255. https://doi.org/10.1158/2159-8290.CD-15-0843 CrossRefPubMed

Shalapour S, Lin XJ, Bastian IN et al (2017) Inflammation-induced IgA⁺ cells dismantle anti-liver cancer immunity. Nature 551:340–345. https://doi.org/10.1038/nature24302 CrossRefPubMedPubMedCentral

Cooper MD (2015) The early history of B cells. Nat Rev Immunol 15:191–197. https://doi.org/10.1038/nri3801 CrossRefPubMed

Vidard L, Kovacsovics-Bankowski M, Kraeft SK, Chen LB, Benacerraf B, Rock KL (1996) Analysis of MHC class II presentation of particulate antigens of B lymphocytes. J Immunol 156:2809–2818PubMed

Senovilla L, Vacchelli E, Galon J et al (2012) Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1:1323–1343. https://doi.org/10.4161/onci.22009 CrossRefPubMedPubMedCentral

10.

Inoue S, Leitner WW, Golding B, Scott D (2006) Inhibitory effects of B cells on antitumor immunity. Cancer Res 66:7741–7747. https://doi.org/10.1158/0008-5472.CAN-05-3766 CrossRefPubMed

11.

Schioppa T, Moore R, Thompson RG, Rosser EC, Kulbe H, Nedospasov S, Mauri C, Coussens LM, Balkwill FR (2011) B regulatory cells and the tumor-promoting actions of TNF-alpha during squamous carcinogenesis. Proc Natl Acad Sci U S A 108:10662–10667. https://doi.org/10.1073/pnas.1100994108 CrossRefPubMedPubMedCentral

12.

Montfort A, Pearce O, Maniati E et al (2017) A strong B-cell response is part of the immune landscape in human high-grade serous ovarian metastases. Clin Cancer Res 23:250–262. https://doi.org/10.1158/1078-0432.Ccr-16-0081 CrossRefPubMed

13.

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:401–404. https://doi.org/10.1158/2159-8290.CD-12-0095 CrossRef

14.

Zhang L, Conejo-Garcia JR, Katsaros D et al (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203–213. https://doi.org/10.1056/NEJMoa020177 CrossRef

15.

Ke AW, Shi GM, Zhou J et al (2009) Role of overexpression of CD151 and/or c-met in predicting prognosis of hepatocellular carcinoma. Hepatology 49:491–503. https://doi.org/10.1002/hep.22639 CrossRefPubMed

16.

Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 102:15545–15550. https://doi.org/10.1073/pnas.0506580102 CrossRefPubMedPubMedCentral

17.

Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453–457. https://doi.org/10.1038/nmeth.3337 CrossRefPubMedPubMedCentral

18.

Murphy K, Weaver C (2016) Janeway’s immunobiology. Garland Science, London. ISBN-13: 978-0-8153-4551-0CrossRef

19.

Qu Y, Chen L, Lowe DB, Storkus WJ, Taylor JL (2012) Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. Mol Ther 20:644–651. https://doi.org/10.1038/mt.2011.283 CrossRefPubMedPubMedCentral

20.

Davis RE, Ngo VN, Lenz G et al (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88–97. https://doi.org/10.1038/nature08638 CrossRefPubMedPubMedCentral

21.

Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265–7279. https://doi.org/10.1038/sj.onc.1206933 CrossRef

22.

Leow JJ, Martin-Doyle W, Rajagopal PS et al (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66:42–54. https://doi.org/10.1016/j.eururo.2013.08.033 CrossRefPubMed

23.

Choi W, Porten S, Kim S et al (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. https://doi.org/10.1016/j.ccr.2014.01.009 CrossRefPubMedPubMedCentral

24.

Fremd C, Schuetz F, Sohn C, Beckhove P, Domschke C (2013) B cell-regulated immune responses in tumor models and cancer patients. Oncoimmunology 2:e25443. https://doi.org/10.4161/onci.25443 CrossRefPubMedPubMedCentral

25.

Shi JY, Gao Q, Wang ZC et al (2013) Margin-infiltrating CD20(+) B cells display an atypical memory phenotype and correlate with favorable prognosis in hepatocellular carcinoma. Clin Cancer Res 19:5994–6005. https://doi.org/10.1158/1078-0432.CCR-12-3497 CrossRefPubMed

26.

DiLillo DJ, Yanaba K, Tedder TF (2010) B cells are required for optimal CD4 + and CD8 + T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 184:4006–4016. https://doi.org/10.4049/jimmunol.0903009 CrossRefPubMedPubMedCentral

27.

Apetoh L, Ghiringhelli F, Tesniere A et al (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13:1050–1059. https://doi.org/10.1038/nm1622 CrossRefPubMed

28.

Wang W, Kryczek I, Dostal L et al (2016) Effector T cells abrogate stroma-mediated chemoresistance in ovarian cancer. Cell 165:1092–1105. https://doi.org/10.1016/j.cell.2016.04.009 CrossRefPubMedPubMedCentral

Title: CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer
Authors: Qi Jiang
Qiang Fu
Yuan Chang
Zheng Liu
Junyu Zhang
Le Xu
Yu Zhu
Yiwei Wang
Weijuan Zhang
Jiejie Xu
Publication date: 01-01-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 1/2019
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-018-2250-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Experimental design

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2019

Recurrent grade 4 panuveitis with serous retinal detachment related to nivolumab treatment in a patient with metastatic renal cell carcinoma

Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer

An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells

TRPM2 modulates neutrophil attraction to murine tumor cells by regulating CXCL2 expression

Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up

Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics

Keynote webinar | Spotlight on antibody–drug conjugates in cancer